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Understanding of the interactions between P-glycoprotem and multidrug resrstance (MDR) reversing agents is important in designing more effective 
MDR modulators. We examined transcellular transport of several MDR modulators by using a drug-sensttive epithelial cell line, LLC-PK,, and 
its transformant cell line. LLC-GAS-COL300, which expresses human P-glycoprotein on the apical surface. Basal-to-apical transports of azidopine 
and diltiazem across the LLC-GAS-COL300 monolayer were increased and apical-to-basal transports were decreased compared to those across 
the LLC-PK, monolayer, indicating that P-glycoprotein transports azidopme and dtltiazem. Movements of nitrendipine and staurosporine across 
the epithelial monolayer were not affected by P-glycoprotein These results suggests that some MDR modulators exert their inhibitory effect not 
only by blocking the initial bindmg of anticancer drugs but throughout the course of the transport process. 
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1. INTRODUCTION 
Multidrug resistance (MDR) is a major clinical prob- 
lem in cancer chemotherapy. The MDR phenotype is 
often associated with high expression levels of the 170- 
kDa P-glycoprotein, which is encoded by the MDRl 
gene in humans [1,2]. P-glycoprotein is believed to act 
as an energy dependent efllux pump for MDR-related 
anticancer drugs. It is well known that some lipophilic 
agents including calcium channel blockers, protein ki- 
nase C inhibitors, and immunosuppressive agents can 
overcome the P-glycoprotein-associated MDR pheno- 
type. However, interactions between P-glycoprotein 
and such MDR modulators have not been fully under- 
stood, although this is important in designing more ef- 
fective modulators. 
The calcium channel blocker verapamil and immuno- 
suppressive agent cyclosporin A. which are among the 
most effective MDR modulators, have been shown to 
compete with Vinca alkaloids in binding to a high-affin- 
ity binding site (a ‘common binding site’) of P-glycopro- 
tein [3,4]. Azidopine, a photoactive analogue of calcium 
channel blockers and also an efficient inhibitor of P- 
glycoprotein, was reported to inhibit Virzca alkaloids 
from binding to P-glycoprotein noncompetitively [5]. 
These results suggest that these agents act as antago- 
nists for the initial binding of Vinea alkaloids. Moreo- 
ver, it has been reported that these agents are excluded 
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from MDR cells but not from sensitive cells, suggesting 
that they are substrates for P-glycoprotein [5-71. This 
suggests that these modulators not only block binding 
of Vinca alkaloids to P-glycoprotein but also have in- 
hibitory effects throughout the course of the transport 
process. These results also make us speculate that it is 
common for MDR modulators to be substrates for P- 
glycoprotein to transport. 
The substrates for P-glycoprotein and MDR modula- 
tors are very lipophilic so that accumulation data have 
sometimes been difficult to interpret due to specific or 
nonspecific adsorption to plasma membranes and fil- 
ters. We have developed a transcellular transport sys- 
tem [8,9] in which human P-glycoprotein was expressed 
specifically on the apical surface of LLC-PK, cells, de- 
rived from the epithelial cells of porcine kidney proxi- 
mal tubule, by introducing human MDRI cDNA iso- 
lated from normal adrenal glands [lo]. Because this 
transcellular transport system is useful to investigate 
P-glycoprotein-mediated transport without the annoy- 
ance of adsorption of lipophilic compounds, we at- 
tempted to discover if several calcium channel blockers 
and staurosporine, known as MDR modulators, are all 
transported by human P-glycoprotein. 
2. EXPERIMENTAL 
2.1. Materials 
[‘H]Azidopine (1920 GBq/mmol, 37 MBq/ml) was obtained from 
Amersham. [lH]Diltiazem (3 185.7 GBq/mmol, 37 MBqlml), [3H]ni- 
trendtpine (2701 GBq/mmol, 37 MBq/ml), [‘Hlstaurosporme (5920 
GBqlmmol, 3.7 MBq/ml), and [‘4C]sucrose (148 MBq/mmol) were 
from DuPont-New England Nuclear. Microplates with bottom-fil- 
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tered cups (Transwell 3414. 24.5 mm m diameter polycarbonate filter 
with tissue culture treatment. 3.0 pm pore size) were from Costar. 
2.2. Trunscellulur transport 
The host cell, LLC-PK, and the transformant cell, LLC-GAS- 
COL300, which expresses human P-glycoprotein on the apical surface 
because of the introduction of human MDRl cDNA, were planted on 
bottom-filtered cups at a density of 4~10~ and 5~10~ cells/cm’, respec- 
tively. LLC-GAS-COL300 was mamtained wrth 300 ng/ml colchicme. 
Cells were Incubated over 3 nights. and media were changed for col- 
chicine-free medium 6 h before expertments. For measurement of 
transcellular transport, the medium of either the basal or the apical 
side of the monolayer was replaced with medium containmg ‘H-la- 
beled MDR modulators and 3.7 kBq/ml (34.8 yM) [r4C]sucrose. The 
cells were incubated at 37°C. Samples (25 ~1) of the medmm of the 
donor and the other side were taken at 1. 2, and 3 h. and the radioac- 
tivities measured. The paracellular fluxes were monitored by measur- 
mg the appearance of [“‘Clsucrose m the other stde. After the 3-h 
sampling, cells were washed with PBS twtce. The filter was cut out of 
the cup, and cells were lysed m 1 ml of 0.3 N NaOH Then protein and 
modulators accumulated m the cells were measured. 
3. RESULTS AND DISCUSSION 
Transcellular transport of [3H]azidopine, a dihy- 
dropyridine calcium channel blocker, was first exam- 
ined (Fig. 1A). The amount of [3H]azidopine moved 
across the epithelial monolayer of the host cell LLC- 
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PK, from the apical to the basal side and that in the 
opposite direction were almost equal, suggesting that 
azidopine moved across the LLC-PK, monolayer by 
simple diffusion. Across the LLC-GAS-COL300 mono- 
layer, basal-to-apical transport of azidopine was greatly 
increased, and apical-to-basal transport was decreased 
compared to those across the host cell monolayer. Be- 
cause P-glycoprotein is specifically expressed on the ap- 
ical surface [8]. intracellular substrates will be selectively 
excreted on the apical side. This selective excretion 
should yield a overall basal-to-apical transport of the 
substrates. The increased basal-to-apical transport and 
the decreased apical-to-basal transport in Fig. 1A sug- 
gests that azidopine is a substrate for P-glycoprotein to 
transport. The intracellular accumulation of azidopine 
after 3 h was significantly decreased in LLC-GAS- 
COL300 cells compared to the host cells, whether 
azidopine was added to the apical or basal medium (Fig. 
1E). This indicates, together with the decreased apical- 
to-basal transport across the LLC-GAS-COL300 mon- 
olayer, that azidopine was actively transported against 
a concentration gradient. 
Nitrendipine, also a dihydropyridine calcium channel 
blocker, inhibits azidopine binding to P-glycoprotein 
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Fig. 1. Transcellular transport of lipophilic MDR modulators. (A-D) Time-dependent movement of MDR modulators through monolayers of the 
host cell line LLC-PK, and the P-glycoprotem-expressing transformant LLC-GAS-COL300 were measured. ‘H-labeled azidopine (A), nitrendipme 
(B), diltiazem (C). or staurosporme (D) was added in the medium of the basal stde (open symbols) or of the aptcal side (closed symbols) of the 
monolayer of LLC-PK, ( I’,@) or LLC-GAS-COL300 (Qm). The amounts of modulators appeared in the media of the opposite side were measured 
after 1. 3, and 3 h and indicated as the fractions of the added amount of modulators. Each point is the average and standard error of three 
independent experiments. The concentrations were as follows: A, 37 kBqlml(19.2 nM) [7H]azidopine; B, 27 kBqlm1 (8.6 nM) [‘Hjmtrendtpme: C, 
37 kBq/ml (10.6 nM) [3H]dilttazem; D, 3.7 kBq/ml (0.63 nM) [3H]staurosporine (E-H) Accumulatton of MDR modulators. Cells were lysed m 
0.3 N NaOH after 3 h, and protein contents and accumulated MDR modulators were measured. Open bar, ‘H-labeled aztdopme (E). nitrendrpine 
(F). diltiazem (G). or staurosporme (H) was added to the basal stde; hatched bar. ‘H-labeled modulators were added to the aptcal side. Data are 
shown as the averages and the standard error of three independent experiments. B and D have already been appeared in a prevrous report as control 
experiments [I 51. 
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[ll], and partially overcomes the MDR phenotype in 
vitro (Ueda, K. et al., unpublished observation). Be- 
cause these results suggest that nitrendipine directly in- 
teracts with P-glycoprotein, it is expected that nitrendip- 
ine is a substrate for P-glycoprotein. However, basal-to- 
apical and apical-to-basal transports of [3H]nitrendipine 
across the LLC-GAS-COL300 monolayer were almost 
identical to those across the host cell monolayer (Fig. 
lB), and no significant difference between intracellular 
accumulation in LLC-GAS-COL300 and that in LLC- 
PK, was observed (Fig. 1F). These results indicate that 
nitrendipine is not a substrate for P-glycoprotein-medi- 
ated transport, and is consistent with the previous re- 
port that there was no difference in binding of [3H]ni- 
trendipine between membrane vesicles prepared from 
the host and MDR cells [12]. 
Next we examined transcellular transport of a benzo- 
diazepine calcium channel blocker, diltiazem. The 
basal-to-apical transport of [3H]diltiazem was increased 
in LLC-GAS-COL300, and apical-to-basal transport 
was decreased compared to those in the host cells, sug- 
gesting that diltiazem was transported by P-glycopro- 
tein (Fig. 1C). However, the amount of diltiazem accu- 
mulated in LLC-GAS-COL300 cells after 3 h was not 
decreased compared to that in LLC-PK, (Fig. 1G). This 
could be explained if diffusion of diltiazem across the 
plasma membrane was so fast (Fig. 1C circles) that 
P-glycoprotein expressed in LLC-GAS-COL300 could 
not decrease the intracellular concentration of dil- 
tiazem. The cellular accumulation of diltiazem in host 
cells was not high as compared to those of azidopine 
and nitrendipine. To measure the cellular accumulation 
after transcellular transport, the cells were washed with 
PBS, and this step required several minutes. Because 
diffusion of diltiazem was fast. considerable amount of 
diltiazem might diffused out of the cells. These results 
suggest that results of accumulation experiments should 
be interpreted carefully in deciding if a substance is a 
substrate for P-glycoprotein to transport. 
In contrast to calcium channel blockers, a protein 
kinase C inhibitor, staurosporine, scarcely moved 
across the epithelial monolayer formed by LLC-PK, as 
well as LLC-GAS-COL300 (Fig. lD), and quite a small 
amount of [3H]staurosporine was accumulated in both 
host and transformant cells (Fig. lH), suggesting that 
[3H]staurosporine could not diffuse through the plasma 
membrane. Although staurosporine was reported to in- 
teract with P-glycoprotein directly in vitro [13], expres- 
sion of P-glycoprotein had no significant effect on the 
movement of [3H]staurosporine in LLC-GAS-COL300. 
Because the cytosolic concentration of staurosporine is 
not considered to be enough to compete with anticancer 
drugs, the concentration of staurosporine dissolved in 
the lipid phase of plasma membrane might be high 
enough to exert an antagonistic effect or to indirectly 
inhibit P-glycoprotein by modulating protein kinase C 
activity in vivo [14]. 
We have reported that the immunosuppressive agents 
cyclosporin A and FK506 are transported by P- 
glycoprotein [15]. These results and the results shown 
here indicate that lipophilic MDR modulators are di- 
vided into two types: ones which are transported by 
P-glycoprotein, and the others which are not. It is sug- 
gested that the former type of modulators, which are 
cyclosporin A, FK506, azidopine, diltiazem, and vera- 
pamil [7] (Saeki, T. et al., unpublished observation), 
exert their inhibitory effect not only by blocking the 
initial binding of anticancer drugs but throughout the 
course of the transport process, but the latter type of 
modulators only block the initial binding. Therefore it 
is conceivable that the former type of modulators are 
more efficient than the latter. Nitrendipine, a latter type 
of modulator, showed only a partial inhibitory effect 
(Ueda, K. et al., unpublished observation) although it 
strongly prevents azidopine photoaffinity labeling in 
vitro [ll]. 
Because P-glycoprotein functions also as a chloride 
channel [16], P-glycoprotein is sometimes thought to 
indirectly mediate drug efllux without actually perform- 
ing active drug transport, e.g. by way of changing intra- 
cellular pH. If this is the case, MDR modulators cannot 
be substrates for P-glycoprotein-mediated transport. By 
using the transcellular transport system, we clearly 
showed that some MDR modulators, which have been 
reported to bind directly to P-glycoprotein and compete 
with anticancer drugs, are substrates for P-glycopro- 
tein-mediated transport. These results suggest that P- 
glycoprotein is directly involved in the active transport 
of anticancer drugs and some MDR modulators against 
concentration gradients, although involvement of indi- 
rect mechanisms are not be excluded. This transepithe- 
ha1 transport system will bring us more detailed insights 
for the mechanism of P-glycoprotein-mediated drug 
transport. 
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